glp-1 medications and alcohol receptor agonists for the treatment of use disorder GLP-1 Medications and Their Impact

While the molecule patents expire in 2026 and 2031, the formulation and delivery patents keep the door locked until 2042

By mimicking the action of natural GLP-1 in the body, these medications help curb hunger signals and reduce food intake, making it easier for individuals to create a calorie deficit and lose weight

An SGLT2 inhibitor with demonstrated evidence of benefit is recommended for individuals with HF with reduced ejection fraction [61,62] or HF with preserved ejection fraction [63,64] [Grade A, Level 1A for dapagliflozin or empagliflozin]

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation

At therapeutic doses, typically 10 to 25 milligrams taken three times daily, it is generally well-tolerated and effective for mild to moderate nausea

Clinicians should treat adherence to GLP-1 treatment as an important outcome in its own right not an afterthought, Al-Aly said